BHP Billiton Limited (ADR)(NYSE:BHP) stock dropped -2.33% in today’s pre market session with the price of $28.95. Over the last one month and over the past three months, BHP Billiton Limited shares gained 12.91% and 9.98%, respectively. Furthermore, the stock has gained 16.50% since the start of this year. The company’s shares are trading 6.23% above their 50-day moving average. Additionally, BHP Billiton Limited has an RSI of 62.40 and beta of 1.49.
BHP Billiton Limited discovers, acquires, develops, and markets natural resources worldwide. It operates through Petroleum and Potash, Copper, Iron Ore, and Coal segments. The company explores for, develops, produces, and markets oil and gas with operating assets in the deep water Gulf of Mexico, Western Australia, Trinidad and Tobago, the United Kingdom, and Pakistan; and owns the Jansen potash project located in the Saskatchewan potash basin in Canada. It also explores for copper, silver, lead, zinc, molybdenum, uranium, gold, iron ore, and seaborne metallurgical and thermal coal. The company was formerly known as BHP Limited and changed its name to BHP Billiton Limited in July 2001. BHP Billiton Limited was founded in 1851 and is headquartered in Melbourne, Australia. BHP Billiton Limited operates as a subsidiary of BHP Billiton Group.
Biogen Inc. (NASDAQ:BIIB) stock on Friday’s pre market session gained 1.14% at price of $257.07. Over the last one month and the previous three months, Biogen Inc’s shares dropped -5.92% and ticked down -0.58%, respectively. Additionally, the stock has plunged -17.03% since the beginning of 2016. The company’s shares are trading above their 50-day and 200-day moving averages by -6.37% and -8.77%, respectively.
June 7, 2016, Biogen (BIIB) reported top-line results from the Phase 2 SYNERGY study evaluating opicinumab (anti-LINGO-1), an investigational, fully human monoclonal antibody being developed as a potential neuroreparative therapy in people with relapsing forms of multiple sclerosis (RMS). In the study, opicinumab missed the primary endpoint, a multicomponent measure evaluating improvement of physical function, cognitive function, and disability. However, evidence of a clinical effect with a complex, unexpected dose-response was observed.
“It is only through taking thoughtful, calculated risks that we can bring major advances to patients,” said Alfred Sandrock, M.D., Ph.D., executive vice president and chief medical officer at Biogen. “Achieving repair of the human central nervous system through remyelination would be a substantial achievement, and while we missed the primary endpoint, the SYNERGY study results suggest evidence of a clinical effect of opicinumab. Due to the complex nature of the data set, we continue to analyze the results to inform the design of our next study.”
Opicinumab also did not meet the secondary efficacy endpoint in SYNERGY, which evaluated the slowing of disability progression. Safety and pharmacokinetics (PK) were also assessed as secondary endpoints. Opicinumab was generally well-tolerated and the safety profile was consistent with what has been observed in prior studies. Opicinumab showed a linear, well-behaved PK profile over the studied dose range. SYNERGY results will be presented at future medical meetings.